An initial two-way ANOVA assessing GFAP+ve staining in the PI of vehicle- and compound A-treated animals reported a significant overall effect of stroke (F1,33 = 89.35, p < 0.0001), but not compound A treatment or an interaction between these factors (Figure 6A). The gene discussed is GFAP; the disease is stroke disorder.